Skip to content
The Nexus
DossierENTITY

ELVN-001

Coverage of ELVN-001 in the Nexus archive.

Earliest in view: Jun 11 · 12:05 UTCMost recent: Jun 11 · 12:05 UTC
Co-mentioned in this coverage
Enliven Therapeuticsorganization1Novartisorganization1Merckorganization1chronic myeloid leukemiatopic1major molecular responsetopic1
Recent coverage
  • HEALTHJun 11 · 12:05 UTCSTAT NEWS
    STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study

    Enliven Therapeutics' leukemia drug, ELVN-001, achieved a 48% major molecular response rate in patients with chronic myeloid leukemia (CML) at 24 weeks. The drug showed higher efficacy in earlier-stage CML patients and outperformed existing treatments from Novartis and Merck in early-stage study results.